Tirzepatide Trial Investigates Reproductive and Metabolic Benefits in PCOS Women

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age, characterized by hormonal imbalances, menstrual irregularity, hyperandrogenism (excess male hormones), and polycystic ovaries. Many women with PCOS also experience overweight or obesity, which exacerbates symptoms and increases risks for type 2 diabetes and cardiovascular disease. While tirzepatide is approved for type 2 diabetes and obesity, its specific impact on ovarian dysfunction and reproductive outcomes in women with PCOS remains largely unexplored.

This study hypothesizes that tirzepatide treatment will demonstrate significant superiority over placebo in improving ovarian dysfunction. Researchers anticipate observing a 40-50% greater improvement in menstrual regularity in the tirzepatide group compared to placebo, potentially leading to more predictable ovulation. Furthermore, given tirzepatide's known metabolic effects, it is expected to induce a 15-20% reduction in body weight and a 10-15% decrease in BMI (Body Mass Index) from baseline. The most significant expected finding is a 2.5-fold increase in the proportion of women achieving regular menstrual cycles with tirzepatide compared to placebo, directly addressing a core PCOS symptom. Secondary outcomes are also expected to show a 20-30% reduction in circulating androgen levels and a 30-45% improvement in insulin sensitivity, both crucial for managing PCOS.